OncoMatch/Clinical Trials/NCT02821013
Duration of Anti-PD-1 Therapy in Metastatic Melanoma
Is NCT02821013 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Intermittent PD-1 inhibitor therapy and Continuous PD-1 inhibitor therapy for unresectable/metastatic melanoma.
Treatment: Intermittent PD-1 inhibitor therapy · Continuous PD-1 inhibitor therapy — The purpose of this study is to compare the effects on patients with metastatic melanoma of taking a government approved and paid-for PD-1 inhibitor intermittently, with taking the same type of agent continuously. Researchers want to see if the two ways of giving this type of treatment work equally well in extending the life of patients with melanoma, or not.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Disease stage
Required: Stage III, IV
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify